Nova Nordisk's Moment with Oral Pill Approval

28 days ago

Nora Melinda

"Clearly people are really interested in this oral pill that we know Nova Nordis just got approval in the US for this or the pill version of its obesity shot WGOI. This is really great news for Nova Nordisk, especially as we think about it in comparison to Eli Lilly, its competitor. Uh they essentially expect to get approval for their version of their oral pill by March. So, we've got Novo Nordis, ticker NVO, in ahead of Elley here. But, I mean, it really is a stock that's been struggling. I'm taking a look at shares of Nova Nordis on a year-to-date basis, down 41%. So, I think that this is really a strong important moment for this company, and you're definitely seeing shares uh clearly investors are liking this. Shares are up as much as 11%. That's the biggest jump we've seen on a single day basis since January for the stock."

The speaker highlights a major catalyst for Nova Nordisk (NVO) with its newly approved oral pill for obesity, contrasting it with competitor Eli Lilly's timeline. Despite being down 41% YTD, the stock experienced an 11% jump, signaling renewed investor interest and a potential near-term turnaround.

Related Stocks